News >

Ivosidenib Improves PFS in IDH1-Mutant Cholangiocarcinoma

Gina Columbus @ginacolumbusonc
Published: Thursday, May 16, 2019

Dr. Chris Bowden
Chris Bowden, MD
Ivosidenib demonstrated a statistically significant improvement in progression-free survival (PFS) by independent radiology review compared with placebo in patients with IDH1-mutant previously treated cholangiocarcinoma, meeting the primary endpoint of the phase III ClarIDHy trial.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x